Version 1
: Received: 21 June 2023 / Approved: 21 June 2023 / Online: 21 June 2023 (15:34:48 CEST)
How to cite:
Vo, N. X.; Le, N. N. H.; Chu, T. D. P.; Pham, H. L.; Dinh, K. X. A.; Tran, T. K.; Bui, T. T. Cost-Utility of Monulpiravir in COVID-19 Treatment: An Estimation in Vietnam Situation. Preprints2023, 2023061574. https://doi.org/10.20944/preprints202306.1574.v1
Vo, N. X.; Le, N. N. H.; Chu, T. D. P.; Pham, H. L.; Dinh, K. X. A.; Tran, T. K.; Bui, T. T. Cost-Utility of Monulpiravir in COVID-19 Treatment: An Estimation in Vietnam Situation. Preprints 2023, 2023061574. https://doi.org/10.20944/preprints202306.1574.v1
Vo, N. X.; Le, N. N. H.; Chu, T. D. P.; Pham, H. L.; Dinh, K. X. A.; Tran, T. K.; Bui, T. T. Cost-Utility of Monulpiravir in COVID-19 Treatment: An Estimation in Vietnam Situation. Preprints2023, 2023061574. https://doi.org/10.20944/preprints202306.1574.v1
APA Style
Vo, N. X., Le, N. N. H., Chu, T. D. P., Pham, H. L., Dinh, K. X. A., Tran, T. K., & Bui, T. T. (2023). Cost-Utility of Monulpiravir in COVID-19 Treatment: An Estimation in Vietnam Situation. Preprints. https://doi.org/10.20944/preprints202306.1574.v1
Chicago/Turabian Style
Vo, N. X., Tu Kim Tran and Tien Thuy Bui. 2023 "Cost-Utility of Monulpiravir in COVID-19 Treatment: An Estimation in Vietnam Situation" Preprints. https://doi.org/10.20944/preprints202306.1574.v1
Abstract
The COVID-19 pandemic has expanded globally and caused serious consequence in both health system and the economy. MPV is one of two oral antivirals for COVID-19 with mild-to-moderate symptoms that have received FDA approval so far. This study aims to evaluate the cost-utility of using MPV in COVID-19 treatment. To compare the utility costs of MPV and non-MPV treatments for COVID-19 patients, we used a decision tree model. Data on clinical efficacy, cost, and quality of life were gathered from previous studies. The incremental effective cost ratio (ICER) calculated based on costs incurred and quality-adjusted life years (QALY), was considered as primary out-come. The total cost of MPV treatment and not using MPV was 15,362,516 VND (618 USD) and 15,771,262 VND (634 USD), respectively. The estimated QALY with using-MPV was 28.33, while without MPV was 19.72. The ICER was dominant, resulting in savings of 47,453 VND/QALY (1.9 USD). MPV is a cost-effective medication used to treat COVID-19. In mild-to-moderate COVID-19 patients, MPV considerably lowers costs and improves quality of life. However, several clinical factors of the drug still need to be taken into account.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.